Integrated Analysis of RNA-Binding Proteins in Glioma
[Paper-level Aggregated] PMCID: PMC7226056
Evidence Type(s): Oncogenic
Summary: Mutation: TERT mutation | Summary: The TERT mutation is associated with glioma formation and is considered a somatic variant contributing to tumor development or progression.
Gene→Variant (gene-first): NA:TERT mutation
Genes: NA
Variants: TERT mutation
Candidate canonical RBDs mainly include the RNA recognition motif (RRM), zinc fingers (ZF), tryptophan-aspartic acid 40 (WD40), K homology (KH) domain, double-stranded RNA-binding motif (DSRM), TUDOR domain, cold shock d
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 7
Evidence Type(s): None
Summary: Not enough information in this passage.
Gene→Variant (gene-first): 7015:tryptophan-aspartic acid 40
Genes: 7015
Variants: tryptophan-aspartic acid 40
Next, we analyzed the expression patterns of RBPs in different types of glioma patients and compared their abundance in expression levels. In our studies, a global analysis of the expression of the mRNA levels of RBPs re
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 5
Evidence Type(s): Oncogenic
Summary: Evidence Type: Oncogenic | Mutation: TERT mutation | Summary: The TERT mutation is associated with glioma formation and is considered a somatic variant contributing to tumor development or progression.
Gene→Variant (gene-first): 7015:CGGA 94) in the TCGA
Genes: 7015
Variants: CGGA 94) in the TCGA
Integrated Analysis of RNA-Binding Proteins in Glioma
[Paper-level Aggregated] PMCID: PMC7226056
Evidence Type(s): Prognostic, Oncogenic
Justification: Prognostic: The text discusses the relationship between the expression of RBPs and clinical outcomes in glioma patients, indicating that molecular alterations can predict therapy response and glioma outcomes. Oncogenic: The mention of TERT mutation in gliomas suggests a role in tumorigenesis, as it is associated with different expression patterns of RBPs and the clinical phenotype of gliomas.
Gene→Variant (gene-first): TERT(7015):CGGA 94) in the TCGA
Genes: TERT(7015)
Variants: CGGA 94) in the TCGA
Candidate canonical RBDs mainly include the RNA recognition motif (RRM), zinc fingers (ZF), tryptophan-aspartic acid 40 (WD40), K homology (KH) domain, double-stranded RNA-binding motif (DSRM), TUDOR domain, cold shock d
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 7
Evidence Type(s): None
Justification: Not enough information in this passage.
Gene→Variant (gene-first): 7015:tryptophan-aspartic acid 40
Genes: 7015
Variants: tryptophan-aspartic acid 40
Next, we analyzed the expression patterns of RBPs in different types of glioma patients and compared their abundance in expression levels. In our studies, a global analysis of the expression of the mRNA levels of RBPs re
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 5
Evidence Type(s): Diagnostic, Oncogenic, Prognostic
Justification: Diagnostic: The passage discusses the reclassification of glioma patients into different types based on expression levels and molecular alterations, indicating that these variants are used to define or classify the disease. Oncogenic: The mention of TERT mutation in gliomas suggests that this somatic variant may contribute to tumor development or progression, as it is associated with different expression levels in tumor types. Prognostic: The passage notes that molecular alterations in gliomas are linked to clinical phenotypes and can predict outcomes, such as overall survival, indicating a prognostic relationship.
Gene→Variant (gene-first): 7015:CGGA 94) in the TCGA
Genes: 7015
Variants: CGGA 94) in the TCGA
Candidate canonical RBDs mainly include the RNA recognition motif (RRM), zinc fingers (ZF), tryptophan-aspartic acid 40 (WD40), K homology (KH) domain, double-stranded RNA-binding motif (DSRM), TUDOR domain, cold shock d
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 7
Evidence Type(s): None
Justification: Not enough information in this passage.
Gene→Variant (gene-first): 7015:tryptophan-aspartic acid 40
Genes: 7015
Variants: tryptophan-aspartic acid 40
Next, we analyzed the expression patterns of RBPs in different types of glioma patients and compared their abundance in expression levels. In our studies, a global analysis of the expression of the mRNA levels of RBPs re
[Paragraph-level] PMCID: PMC7226056 Section: RESULTS PassageIndex: 5
Evidence Type(s): Diagnostic, Oncogenic, Prognostic
Justification: Diagnostic: The passage discusses the reclassification of glioma patients into different types based on expression levels and molecular alterations, indicating that these variants are used to define or classify the disease. Oncogenic: The mention of TERT mutation in gliomas suggests that this somatic variant may contribute to tumor development or progression, as it is associated with different expression levels in tumor types. Prognostic: The passage notes that molecular alterations in gliomas are linked to clinical phenotypes and can predict outcomes, such as overall survival, indicating a prognostic relationship.
Gene→Variant (gene-first): 7015:CGGA 94) in the TCGA
Genes: 7015
Variants: CGGA 94) in the TCGA